Recent Events & Catalysts
Protagonist Therapeutics, Inc. (PTGX) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
Benzinga · 1d ago
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173
Benzinga · 1d ago
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Benzinga · 1d ago
Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186
Benzinga · 1d ago
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153
Benzinga · 5d ago
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate
Benzinga · 6d ago
SEC Filings (90 days)
Results of operations (earnings release), Regulation FD disclosure, Financial statements and exhibits
Filed 2026-08-05 · 6d ago · Material
Departure/appointment of directors or officers, Submission of matters to a vote of security holders, Financial statements and exhibits
Filed 2026-06-18 · 54d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.